3 citations
,
March 2018 in “European Urology Supplements” Using 5-alpha-reductase inhibitors may improve bladder cancer survival in men.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
2 citations
,
July 2006 in “European Urology Supplements” 5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
January 2015 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
5-ARI therapy may help prevent prostate cancer progression.
Self-monitoring blood pressure in pregnant women didn't improve outcomes, diabetes drugs may increase gallbladder disease risk, a new drug helps severe hair loss, a plant-based COVID-19 vaccine is 69.5% effective, and new anticoagulants are safer for diabetics with heart rhythm issues than warfarin.
14 citations
,
January 2020 in “International Journal of Biological Sciences” Ranitidine and finasteride lower TMAO levels, reducing heart and kidney damage by changing gut bacteria.
October 2019 in “European heart journal” Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.
45 citations
,
April 2021 in “Current Treatment Options in Oncology” ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
7 citations
,
January 2013 in “European Urology” 5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
4 citations
,
January 1990 in “Journal of Dermatological Treatment” Stopping captopril resolved the skin and hair issues, suggesting it caused them.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
4 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
15 citations
,
October 2014 in “Hormone Molecular Biology and Clinical Investigation” Some hair loss and prostate drugs might increase the risk of diabetes and heart disease.
34 citations
,
September 2013 in “Urology” Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.
6 citations
,
August 2017 in “Physiological Research” Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
6 citations
,
June 2022 in “Journal of Clinical Medicine” Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.